Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

217
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
217
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

231
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
231
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

322
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
322
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.2K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuberculosis before and during COVID-19 Pandemic, United States, 2010-2023.

Emerging infectious diseases·2026
Same author

Opportunities in stroke care at safety net hospitals: A socioecological perspective.

Equity neuroscience·2025
Same author

Tuberculosis Infection among Non-US-Born Persons and Persons ≥60 Years of Age, United States, 2019-2020.

Emerging infectious diseases·2023
Same author

Factors Associated With Receiving Longer Than Recommended Therapy Among Culture-Negative Pulmonary Tuberculosis Patients.

Open forum infectious diseases·2022
Same author

Epidemiology of Pediatric Multidrug-Resistant Tuberculosis in the United States, 1993-2014.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2017
Same author

Tuberculosis - United States, 2016.

MMWR. Morbidity and mortality weekly report·2017
Same journal

Surveillance for Candida auris - United States, 2022-2024.

Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)·2026
Same journal

Foodborne Disease Outbreaks Associated with Marine Toxins - Foodborne Disease Outbreak Surveillance System, United States, 2011-2023.

Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)·2026
Same journal

Brucellosis Surveillance - United States, 2010-2024.

Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)·2026
Same journal

Tetanus Surveillance - United States, 2009-2023.

Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)·2026
Same journal

Surveillance for Violent Deaths - National Violent Death Reporting System, 50 States, the District of Columbia, and Puerto Rico, 2022.

Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)·2025
Same journal

Population-Based Active Surveillance for Culture-Confirmed Candidemia - 10 Sites, United States, 2017-2021.

Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)·2025
See all related articles

Related Experiment Video

Updated: Jun 24, 2025

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.8K

Progress Toward Tuberculosis Elimination and Tuberculosis Program Performance - National Tuberculosis Indicators

Rachel Woodruff1, Robert Pratt1, Maureen Kolasa1

  • 1Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC.

Morbidity and Mortality Weekly Report. Surveillance Summaries (Washington, D.C. : 2002)
|June 4, 2024
PubMed
Summary
This summary is machine-generated.

National TB Indicators Project data show improvements in tuberculosis (TB) control activities. Most TB programs enhanced efforts in reducing TB incidence and ensuring treatment completion for latent TB infection (LTBI).

More Related Videos

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.2K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K

Related Experiment Videos

Last Updated: Jun 24, 2025

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.8K
Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.2K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K

Area of Science:

  • Public Health
  • Epidemiology
  • Infectious Disease Control

Background:

  • Tuberculosis (TB) elimination is defined as reducing incidence to <1 case per million.
  • In 2022, US TB incidence was 2.5 cases per 100,000.
  • CDC developed national TB indicators to monitor program performance.

Purpose of the Study:

  • Evaluate progress toward TB elimination using national TB indicators.
  • Identify areas for program evaluation and improvement.
  • Assist CDC in identifying programs needing technical assistance.

Main Methods:

  • Utilized the National TB Indicators Project (NTIP), a web-based tool.
  • Analyzed 5-year data (2016-2022) for five key TB indicators.
  • Calculated relative change in indicator performance for 52 TB programs.

Main Results:

  • Most programs improved in reducing overall TB incidence (71.2%) and increasing LTBI treatment completion (55.8%).
  • Over half of programs (51.0%) reduced TB incidence among non-U.S.-born persons.
  • Approximately two-thirds of programs met or exceeded national averages for drug susceptibility testing and therapy completion.

Conclusions:

  • This report is the first to show 5-year relative changes in TB program performance.
  • Results indicate improvements in identifying TB/LTBI and ensuring timely treatment completion.
  • NTIP data facilitate program comparison, resource allocation, and policy development.